Phase 1 Trial: Next-Gen PSMA Radioligand 177Lu-LNC1011 Shows Favorable Results

/in , , /by

177Lu-D-Dan-Phe-PSMA, also called 177Lu-LNC1011, represents a next-generation PSMA-targeted radioligand therapy designed to improve on existing options like Pluvicto for metastatic castration-resistant prostate cancer (mCRPC). Unlike Pluvicto, which clears rapidly through the kidneys and limits sustained tumor exposure, this agent incorporates a dansyl modification for prolonged intratumoral retention while preserving systemic clearance. Early phase 1 results […]

Read more

AKY-2519: Phase 1b Trial Targets B7-H3 in Metastatic Prostate Cancer

/in , , /by

AKY-2519, a miniprotein radioconjugate targeting B7-H3, has entered a Phase 1b clinical trial in patients with metastatic castration-resistant prostate cancer (mCRPC). The open-label study enrolls both PLUVICTO-naïve and PLUVICTO-experienced patients at multiple U.S. radioligand therapy centers, evaluating three dose levels in each cohort before expanding at selected doses. Preliminary safety and efficacy data from this […]

Read more

TLX597-Tx Shows Early Promise in a Phase 2 PSMA Trial for Prostate Cancer

/in , , /by

TLX597-Tx (177Lu-DOTA-HYNIC-panPSMA) is emerging as a next-generation PSMA-targeted radioligand therapy designed to deliver radiation more precisely to prostate cancer cells while limiting exposure to healthy organs. New data from the OPTIMAL-PSMA trial suggest that the drug may achieve strong tumor uptake with relatively low dose to the salivary glands and kidneys, two of the main […]

Read more

Phase 2 ARTEMIS-003 Trial: HS-20093 for mCRPC

/in , , /by

HS-20093  has received Breakthrough Therapy designation from China’s National Medical Products Administration for metastatic castration-resistant prostate cancer. The designation covers patients previously treated with novel endocrine therapy and taxane-based chemotherapy, a setting where later-line treatment options remain limited. HS-20093 is a B7-H3-targeted antibody-drug conjugate designed to bind tumor cells expressing B7-H3 and deliver a cytotoxic […]

Read more

Phase 1 Study of BPX-601: A Controlled Immune Therapy for Advanced Prostate Cancer

/in , , /by

A new clinical trial has recently begun for a promising but complex type of cancer treatment called BPX-601, designed specifically for men dealing with advanced prostate cancer that has stopped responding to traditional therapies. This therapy is a form of CAR T-cell treatment, which means doctors take a patient’s own immune cells, reprogram them in […]

Read more

Double-Masked PSMA-TCE JANX014 Enters Phase 1 for mCRPC

/in , , /by

A novel double-masked T-cell engager targeting prostate-specific membrane antigen (PSMA), called JANX014, has entered phase 1 testing in patients with metastatic castration-resistant prostate cancer (mCRPC). The first-in-human, open-label, multicenter trial, which dosed its initial participant in mid-April 2026, evaluates safety, tolerability, pharmacokinetics, pharmacodynamics, and early antitumor activity through ascending intravenous doses administered as monotherapy to […]

Read more

Phase 1/2 RAISIC‑1 Trial: PTT‑4256 in Advanced Solid Tumors

/in , , , /by

PTT‑4256 is an emerging first‑in‑class small‑molecule inhibitor of GPR65, a proton‑sensing G‑protein‑coupled receptor selectively expressed on immune cells within the acidic tumour microenvironment. It is being evaluated in the RAISIC‑1 trial, a modular, open‑label, phase 1/2 study in patients with advanced solid tumours designed to assess safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy. The trial’s […]

Read more

Phase 1/2 Trial for AZD8359: a CD8-Biased T Cell Engager Targeting STEAP2 in m CRPC

/in , , , /by

Bispecific T cell engagers, while conceptually powerful, have carried a toxicity profile that constrains their clinical utility. AZD8359, a novel trispecific T cell engager now entering its first-in-human clinical trial, represents a thoughtful attempt to resolve that toxicity problem at the molecular engineering level, and its preclinical data are among the most compelling seen in this […]

Read more

UPDATE: Phase 1 Trial of HSK46575, a Novel CYP11A1 Inhibitor for Advanced Prostate Cancer

/in , , /by

HSK46575, a novel CYP11A1 inhibitor designed to suppress the entire steroidogenesis pathway, continues to generate interest in advanced prostate cancer, with new early-phase clinical data providing a clearer picture of its activity and tolerability in patients. At the latest data cut-off, 27 patients with advanced prostate cancer had been treated across dose-escalation cohorts ranging from […]

Read more

DLL3-Targeted ADC ZL-1310 Shows Early Promise in Neuroendocrine Carcinomas

/in , , /by

Early-phase data from the ZL-1310-002 trial introduce a potentially important new therapeutic option for patients with advanced neuroendocrine carcinomas (NECs), a group of aggressive malignancies with very limited treatment options after platinum-based chemotherapy. Among these, neuroendocrine prostate cancer (NEPC) represents one of the most clinically challenging subtypes, characterized by rapid progression, resistance to androgen receptor–targeted […]

Read more